Neoleukin Therapeutics Inc (NLTX)
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price & Analysis

405 Followers

NLTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.38 - $3.84
Previous Close$0.6
Volume20.32K
Average Volume (3M)288.84K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$106.88M
Total Debt (Recent Filing)$12.07M
Price to Earnings (P/E)-0.5
Beta1.34
Next EarningsMar 16, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.16
Shares Outstanding42,594,602
R-Squared0.05
Standard Deviation0.28
10 Day Avg. Volume106,324
30 Day Avg. Volume288,836
Price to Book (P/B)0.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside116.70% Upside
Rating ConsensusHold
Alpha-0.02
Number of Analyst Covering5


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NLTX FAQ

What was Neoleukin Therapeutics’s price range in the past 12 months?
Neoleukin Therapeutics lowest stock price was $0.38 and its highest was $3.84 in the past 12 months.
    What is Neoleukin Therapeutics’s market cap?
    Currently, no data Available
    When is Neoleukin Therapeutics’s upcoming earnings report date?
    Neoleukin Therapeutics’s upcoming earnings report date is Mar 16, 2023 which is in 46 days.
      How were Neoleukin Therapeutics’s earnings last quarter?
      Neoleukin Therapeutics released its earnings results on Nov 14, 2022. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.064.
        Is Neoleukin Therapeutics overvalued?
        According to Wall Street analysts Neoleukin Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Neoleukin Therapeutics pay dividends?
          Neoleukin Therapeutics does not currently pay dividends.
          What is Neoleukin Therapeutics’s EPS estimate?
          Neoleukin Therapeutics’s EPS estimate is -$0.21.
            How many shares outstanding does Neoleukin Therapeutics have?
            Neoleukin Therapeutics has 42,594,600 shares outstanding.
              What happened to Neoleukin Therapeutics’s price movement after its last earnings report?
              Neoleukin Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went down -20.755%.
                Which hedge fund is a major shareholder of Neoleukin Therapeutics?
                Among the largest hedge funds holding Neoleukin Therapeutics’s share is Royce & Associates LLC. It holds Neoleukin Therapeutics’s shares valued at 93K.

                  ---

                  Neoleukin Therapeutics Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -81.33%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -45.51%
                  Trailing 12-Months
                  Asset Growth
                  -28.05%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Neoleukin Therapeutics Inc

                  Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Tonix Pharma
                  Verici Dx Plc
                  Elevation Oncology
                  RegeneRx Biopharmaceuticals
                  bioAffinity Technologies, Inc.

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis